Optimize adherence, lifestyle changes, and statin usage before adding a non-statin drug; if a patient has an LDL-C level > 70 mg / dL (> 1.8 mmol / L) with high risk atherosclerotic cardiovascular disease, adding ezetimibe or PSCK9 inhibitor is reasonable.